Skip Navigation


Carcinogenesis Advance Access originally published online on March 29, 2006
Carcinogenesis 2006 27(9):1778-1786; doi:10.1093/carcin/bgl016
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary data
Right arrow All Versions of this Article:
27/9/1778    most recent
bgl016v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (11)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Packer, L.
Right arrow Articles by Hayward, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Packer, L.
Right arrow Articles by Hayward, N.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN

Leisl Packer*, Sandra Pavey, Andrew Parker1, Mitchell Stark, Peter Johansson2, Belinda Clarke3, Pamela Pollock4, Markus Ringner2 and Nicholas Hayward

Human Genetics Laboratory, Queensland Institute of Medical Research Herston 4006, QLD, Australia
1 Department of Cellular Pathology, John Radcliffe Hospital Oxford OX3 9DU, UK
2 Department of Theoretical Physics, Lund University Lund SE-223 62, Sweden
3 Queensland Health Pathology Services, Prince Charles Hospital Brisbane 4032, Australia
4 Melanoma Genetics Research Unit, Translational Genomics Research Institute Phoenix 85004, USA

*To whom correspondence should be addressed. Tel: +61 7 3362 0308; Fax: +61 7 3845 3508; Email: Leisl.Packer{at}qimr.edu.au

The tumor suppressor PTEN antagonizes phosphatidylinositol 3-kinase (PI3K), which contributes to tumorigenesis in many cancer types. While PTEN mutations occur in some melanomas, their precise mechanistic consequences have yet to be elucidated. We sought to identify novel downstream effectors of PI3K using a combination of genomic and functional tests. Microarray analysis of 53 melanoma cell lines identified 610 genes differentially expressed (P < 0.05) between wild-type lines and those with PTEN aberrations. Many of these genes are known to be involved in the PI3K pathway and other signaling pathways influenced by PTEN. Validation of differential gene expression by qRT–PCR was performed in the original 53 cell lines and an independent set of 18 melanoma lines with known PTEN status. Osteopontin (OPN), a secreted glycophosphoprotein that contributes to tumor progression, was more abundant at both the mRNA and protein level in PTEN mutants. The inverse correlation between OPN and PTEN expression was validated (P < 0.02) by immunohistochemistry using melanoma tissue microarrays. Finally, treatment of cell lines with the PI3K inhibitor LY294002 caused a reduction in expression of OPN. These data indicate that OPN acts downstream of PI3K in melanoma and provides insight into how PTEN loss contributes to melanoma development.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
CarcinogenesisHome page
J. Shao, M.K. Washington, R. Saxena, and H. Sheng
Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin
Carcinogenesis, December 1, 2007; 28(12): 2476 - 2483.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Stark and N. Hayward
Genome-Wide Loss of Heterozygosity and Copy Number Analysis in Melanoma Using High-Density Single-Nucleotide Polymorphism Arrays
Cancer Res., March 15, 2007; 67(6): 2632 - 2642.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.